No replication of previously reported association with genetic variants in the T cell receptor alpha (TRA) locus for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Marthe Ueland1, Riad Hajdarevic1,2, Olav Mella3,4, Elin B. Strand5,6, Daisy D. Sosa7,8, Ola D. Saugstad9, Øystein Fluge3,4, Benedicte A. Lie1,2,10 and Marte K. Viken1,10,53

© The Author(s) 2022

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disease with a variety of symptoms such as post-exertional malaise, fatigue, and pain, but where aetiology and pathogenesis are unknown. An increasing number of studies have implicated the involvement of the immune system in ME/CFS. Furthermore, a hereditary component is suggested by the reported increased risk for disease in relatives, and genetic association studies are being performed to identify potential risk variants. We recently reported an association with the immunologically important human leucocyte antigen (HLA) genes HLA-C and HLA-DQB1 in ME/CFS. Furthermore, a genome-wide genetic association study in 42 ME/CFS patients reported significant association signals with two variants in the T cell receptor alpha (TRA) locus (P value <5 × 10−8). As the T cell receptors interact with the HLA molecules, we aimed to replicate the previously reported findings in the TRA locus using a large Norwegian ME/CFS cohort (409 cases and 810 controls) and data from the UK biobank (2105 cases and 4786 controls). We investigated numerous SNPs in the TRA locus, including the two previously ME/CFS-associated variants, rs11157573 and rs17255510. No associations were observed in the Norwegian cohort, and there was no significant association with the two previously reported SNPs in any of the cohorts. However, other SNPs showed signs of association (P value <0.05) in the UK Biobank cohort and meta-analyses of Norwegian and UK biobank cohorts, but none survived correction for multiple testing. Hence, our research did not identify any reliable associations with variants in the TRA locus.

Translational Psychiatry (2022) 12:277; https://doi.org/10.1038/s41398-022-02046-1

INTRODUCTION

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling disease estimated to affect from 0.2 to 2% of the population, depending on the diagnostic criteria used [1]. No biomarkers exist [2]. Thus, diagnosis is based on the presence of core symptoms (e.g. post-exertional malaise, fatigue and pain) and exclusion of other possible illnesses using one of the proposed diagnostic criteria, such as Canadian Consensus Criteria, International Consensus Criteria or Fukuda Criteria [3–5]. The aetiology and pathogenesis of ME/CFS are poorly understood, however, there is increasing evidence pointing towards an immunological component. Elevated levels of autoantibodies against β2 adrenergic receptors, and muscarinic 3 and 4 acetylcholine receptors have been reported [6, 7]. Additionally, decreased cytotoxicity of CD8+ T cells [8] and increased presence of autoreactive T cells [9] have also been observed in ME/CFS patients.

A heritable component is implicated by the reported increased risk in relatives of ME/CFS patients [10–12], and genetic association studies are emerging in order to identify risk variants. We have recently reported associations with specific HLA alleles, HLA-C*07:04 and HLA-DQB1*03:03 [13], and individuals carrying either one or both risk alleles seem to more often respond positively to the immunosuppressive drug cyclophosphamide [14]. The HLA locus is well-documented as the main genetic determinant in other immune-mediated diseases, such as multiple sclerosis and rheumatoid arthritis [15]. The functional role of the HLA molecules in presenting peptides to the T cell receptors (TCRs), also makes the latter genes prime candidates for involvement in disease predisposition.

The TCR diversity is driven by somatic recombination between different variable (V), diversity (D) and joining (J) gene segments, a process guided by recombination signal sequences (RSS) [16]. SNPs located in the RSS have been suggested to influence the gene usage during the V(D)J recombination [17], and thus also affect the TCR repertoire.

Genetic variation within the TCR locus encoding the T cell receptor alpha (TRA) has previously been found to be associated with multiple sclerosis [18] and narcolepsy [19]. Furthermore,
and Health Research Ethics (REK, 2015/1547). Genotyping data for the TRA research project was approved by the Regional Committees for Medical and Health Research Ethics. Patients with DNA currently available were included in this study. The controls. All patients have previously been included in association studies (18%) in ME/CFS patients, and 448 females (55%) and 362 males (45%) in controls. We only allowed SNPs with a genotype success rate >95% and being in Hardy–Weinberg equilibrium (P value >0.001) to be included in our association analyses.

Power calculations
Our study had more than 80% power to detect genotype risk ratios >1.33 for a multiplicative or additive disease model, respectively, using the Genetic Association Study (GAS) power calculator (https://csg.sph.umich.edu/abecasis/gas_power_calculator/) with the settings: significance level = 0.05, prevalence = 0.02 and allele frequencies from 0.27 in the Norwegian cohort.

RESULTS
The genotyping success rate was >99.7% across all 30 SNPs, and no significant deviation from Hardy–Weinberg equilibrium was observed. ME/CFS patients and controls displayed a similar linkage disequilibrium (LD) pattern across the TRA locus, with few SNPs showing strong LD (r² > 0.90, supplementary Fig. 1).

We first analysed the Norwegian ME/CFS cohort, where the patients had been diagnosed according to the Canadian Consensus Criteria (409 cases and 810 controls). Association analyses of the 30 SNPs across the TRA locus did not show any significant differences (P value >0.05) in allele frequencies between the Norwegian ME/CFS patient and controls (Fig. 1A and supplementary Table 1). Nor were there any significant differences between males and females. As the TRA locus is a complex genetic region, single SNP associations might not detect potential association signals. Thus, we next performed two-locus haplotype analyses, which did not show signs of associations (P value >0.05, the top hit was for rs2001022 and rs11626312 with a P value = 0.07).

Given the biological interactions between HLA and TCR, one could hypothesise that the TRA association could be more evident in the subset of ME/CFS patients carrying the HLA-risk alleles (HLA-C*07:04 and/or -DQB1*03:03). However, no significant differences were observed for the TRA allele frequencies between Norwegian ME/CFS patients being HLA-risk allele carriers vs non-carriers.

M. Ueland et al.

Fig. 1  Association analyses of the TRA locus. LocusZoom plot of the 30 SNPs covering the TRA locus from A the Norwegian cohort, B the UK Biobank cohort and C meta-analysis of the Norwegian and UK biobank cohorts. The y axis is showing the –log10(P value) while the x-axis is showing the base pair position on chromosome 14. SNPs are marked as dots and recombination rate by blue lines on the plot. Notably, the previously associated SNPs, rs17255510 and rs11157573, are marked as squares. The colour of the SNPs indicates the LD measured in r². The red line represents P value = 0.05.
Next, we also investigated the same 30 SNPs using a cohort of self-reported CFS patients (2105 cases and 4786 controls) from the UK biobank. The two previously ME/CFS-associated SNPs, rs11157573 and rs17255510 showed no signs of association in the UK cohort either (Fig. 1B). However, three SNPs had a \( P \) value <0.05 (rs17183131, rs8021297 and rs8005677, Fig. 1B). In a meta-analysis of both the Norwegian and UK cohort, two of these SNPs, rs8021297 (\( P \) value = 0.02) and rs17183131 (\( P \) value = 0.03), still showed weak signs of association (Fig. 1C). Stratifying for HLA-risk allele carriers versus non-carriers in the combined Norwegian (73 carriers, 336 non-carriers) and UK dataset (294 carriers, 1811 non-carriers) displayed only one SNP, rs8572 (\( OR = 0.76, \ P \) value = 0.03), with \( P \) value <0.05 (Supplementary Table 1). None of these SNPs reached a Bonferroni corrected significance threshold of \( P \) value <0.002 when correcting for the 30 SNPs tested.

When including all SNPs (\( N = 6769 \)) in the TRA region from the UK Biobank dataset, there were 272 SNPs showing signs of association (\( P \) value <0.05), with the most significant being rs8016431 (\( OR = 0.88, \ 95\% CI (0.80–0.95), \ P \) value = 0.0015, Fig. 2). However, these had a \( P \) value that could not withstand correction for multiple testing (\( P \) value <7.4 \times 10^{-5} \).

The SNPs, rs11157573 and rs17255510, previously reported by Schlauch et al. to be ME/CFS-associated [20], had similar allele frequencies in the Norwegian and UK biobank datasets (Table 1). These frequencies did not deviate between cases and controls (\( P \) value >0.05). Furthermore, these frequencies were similar to that seen in the 1000 Genomes CEU dataset. The control frequencies reported by Schlauch et al. were comparable to that observed in our control datasets from Norway and the UK, as well as in the CEU cohort from the 1000 Genomes. However, Schlauch et al. reported vastly increased case frequencies compared to what we observed for rs17255510 and rs11157573 (see Table 1). Differences in allele frequencies could be due to different ethnicities, however, the ethnicity of the cohort investigated by Schlauch et al. is not stated in their article. Furthermore, the magnitude of the differences in frequencies they observed between their cases and controls is far beyond what is generally reported in complex diseases.

Other factors might have influenced the discrepancies between our studies. Clinical manifestations in ME/CFS cases are known to be heterogeneous [29]. Both Schlauch et al. (\( N = 42 \)) and our Norwegian (\( N = 409 \)) ME/CFS patients met the Canadian Consensus Criteria for diagnosis, while the patients (\( N = 2105 \)) from the UK cohort were self-reported. Furthermore, the variation in sample size between the cohorts affect their statistical power. As an example, our study only had 80% power to detect associations at a significance level of 0.05 for \( OR >1.33 \), while a study with 100 cases and 100 controls (twice the size of the Schlauch et al. study) using the same calculation settings only have ~27% statistical power. Studies with few individuals are more affected by random effects like selection bias and genotyping errors [30]. Hence, increasing the chance of false-positive discoveries.

The sample size of our study is larger than that of Schlauch et al., but nevertheless suboptimal to detect significance for low effect sizes typically seen for complex diseases [31]. Studies unable to replicate an initially reported association often show consistent results with the initial observation, but lack the power to detect it [32]. A 1% difference in allele frequencies between cases and controls was seen for some of the tested SNPs in our dataset, which, if representing a genuine difference, could reach significance in a much larger population. Hence, the lack of association in this study cannot be used to conclude that TRA is not involved in the pathogenesis of ME/CFS. This is underpinned by the signs of association observed in the self-reported UK cohort, which did not withstand correction for multiple testing. Further studies and meta-analyses are necessary to either confirm or reject an association between TRA and ME/CFS. Reliable findings will be achieved both by including more patients and controls as well as a denser set of SNPs across the TRA region. The DecodeME initiative (https://www.decodeme.org.uk/), with the

| SNPs       | Allele | Cases | Controls | Cases | Controls | Cases | Controls | General |
|------------|--------|-------|----------|-------|----------|-------|----------|---------|
| rs17255510 | C      | 0.220 | 0.218    | 0.214 | 0.234    | 0.679 | 0.171    | 0.232   |
| rs11157573 | C      | 0.180 | 0.184    | 0.171 | 0.178    | 0.488 | 0.158    | 0.197   |

Table 1. Overview of the allele frequencies for rs17255510 and rs11157573 observed in our Norwegian 409 ME/CFS cases and 810 controls, the UK biobank with 2105 ME/CFS cases and 4786 controls compared to frequencies from the previous publication by ref. [20], and the 1000 genomes project (CEU, Northern Europeans from Utah) [33].
goal of recruiting 20,000 ME/CFS patients, will hopefully enable robust association studies with good statistical power.

Taken together, the current study, which to date represents by far the largest study addressing the association between the TRA locus and ME/CFS, could not find any association.

REFERENCES

1. Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020;18:100.

2. Valdez AR, Hancock EE, Adebayo S, Kiernicki DJ, Proskauer D, Attewell JR, et al. Estimating prevalence, demographic, and costs of ME/CFS using large scale medical claims data and machine learning. Front Pediatr. 2018;6:412.

3. Carruthers BM, van de Sande MJ, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;269:327–38.

4. Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7–115.

5. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobkins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Inter- national chronic fatigue syndrome study group. Ann Intern Med. 1994;121:953–9.

6. Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. Immunoadsorption to remove α2 adrenergic receptor antibodies in chronic fatigue syndrome CFS/ME. PLoS ONE. 2018;13:e0193672.

7. Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Anti-bodies to α2 adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun. 2016;52:32–39.

8. Sotzny F, Blanco J, Capelli E, Castro-Marrero J, Steiner S, Murovska M, et al. Myalgic encephalomyelitis/chronic fatigue syndrome—evidence for an autoimmune disease. Autoimmun Rev. 2018;17:601–9.

9. Morris G, Berk M, Galecki P, Maes M. The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs). Mol Biolog. 2014;9:471–56.

10. Allbright F, Light K, Light A, Bateman L, Cannon-Albright LA. Evidence for a heritable predisposition to chronic fatigue syndrome. BMC Neurol. 2011;11:62.

11. Walsh CM, Zainal NZ, Middleton SJ, Paykel ES. A family history study of chronic fatigue syndrome. Psychiatr Genet. 2001;11:123–8.

12. Buchwald D, Herrell R, Ashton S, Belcourt M, Schmaling K, Sullivan P, et al. A twin study of chronic fatigue. Psychosom Med. 2001;63:936–43.

13. Lande A, Flueg O, Strand EB, Flam ST, Sosa DD, Mella O, et al. Human leukocyte antigen alleles associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Scip Rep. 2020;10.

14. Rekeland IG, Fossa A, Lande A, Ktiroudou-Valen I, Sorland K, Holsen M, et al. Intravenous cyclophosphamide in myalgic encephalomyelitis/chronic fatigue syndrome. An open-label phase II study. Front Med. 2020;7:162.

15. Thursby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases; genes involved and possible mechanisms. Transpl Immunol. 2005;14:175–82.

16. McMurry MT, Hernandez-Munain C, Lazzurica P, Krangel MS. Enhancer control of local accessibility to V(D)J recombinase. Mol Cell Biol. 1997;17:4533–61.

17. Posnett DN, Vissinga CS, Pambuccian C, Wei S, Robinson MA, Kostyu D, et al. Leishmania TCRBV335 (V beta 3) expression correlates with allelic polymorphism in the spacer region of the recombination signal sequence. J Exp Med. 1994;179:1077–11.

18. Watson CT, Para AE, Lincoln MR, Ramagopalan SV, Orton SM, Morrison KM, et al. Revisiting the T-cell receptor alpha/delta locus and possible associations with multiple sclerosis. Genes Immun. 2011;12:59–66.

19. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al. Narecppez is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41:708–11.

20. Schlauch KA, Khaiboullina SF, De Meirleir KL, Rawat S, Peteriet E, Rizvanov AA, et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome. Transl Psychiatry. 2016;6:e730.

21. Hajdarevic R, Lande A, Rekeland I, Rydland A, Strand EB, Sosa DD, et al. Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci. Brain Behav Immun. 2021;98:101–9.

22. Hajdarevic R, Lande A, Mehlsen J, Rydland A, Sosa DD, Strand EB, et al. Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci. Brain Behav Immun. 2022;102:362–9.

23. International Multiple Sclerosis Genetics, C, Beecham AH, Patapolou NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353–60.

24. Liu JZ, Hov JR, Folsenaas T, Ellingshaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45:670–5.

25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.

26. Barrett JC, Fry B, Maller J, Daly MJ. Haplview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.

27. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336–7.

28. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 2008;66:87–98.

29. Friedman KJ. Advances in ME/CFS: past, present, and future. Front Pediatr. 2019;7:133.

30. Colonn HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865–72.

31. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inf. 2012;10:117–22.

32. Altschuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science. 2008;322:881–8.

33. Genomes Project, C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;525:68–74.

ACKNOWLEDGEMENTS

We are very thankful to the participants who participated in the study, and the controls recruited through the Norwegian Bone Marrow Donor Registry. This research has been conducted using the UK Biobank Resource under Application Number 43949. Thank you to Kari Sarlø, Kine Alme and Kristin Risa at the Department of Oncology and Medical Physics, Haukeland University Hospital, Wenche Kristiansen and Hilde Haukeland at the CFS/ME Biobank, Oslo University Hospital, Asgeir Lande, Anne Rydland and Siri T. Fålam at Department of Medical Genetics, Oslo University Hospital, and employees at the Genomics Core Facility, Oslo University Hospital, Norway for all their help. This work has received financial support from the Research Council of Norway (project 272681) and the Norwegian ME association.

AUTHOR CONTRIBUTIONS

MU: Laboratory analyses, data analyses, writing of original draft, reviewing and editing subsequent drafts; RH: Data analyses, writing and reviewing; OM: Resources, writing and reviewing; EBS: Resources and reviewing; DDS: Resources and reviewing; ODS: Supervision, writing and reviewing; BF: Resources, writing and reviewing; BAL: Conceptualisation, methodology, supervision, funding acquisition, resources, writing of original draft, reviewing and editing subsequent drafts; MKV: Conceptualisation, methodology, supervision, funding acquisition, resources, writing of original draft, reviewing and editing subsequent drafts.

COMPETING INTERESTS

MKV has received funding from the Norwegian ME Association, which partly funded the study. No funding bodies have been involved in the planning, design or execution of the study.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-02046-1.

Correspondence and requests for materials should be addressed to Marte K. Viken.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
